High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To report the rates of grade IV adverse events and hepatitis C virus (HCV) treatment discontinuation associated with the use of telaprevir, pegylated interferon, and ribavirin.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): AIDS

Title: AIDS (London, England)

ISSN (Electronic): 1473-5571

ISSN (Print): 0269-9370

Publication date (Electronic): Nov 28 2013

Volume: 27

Issue: 18

Affiliations

[1 ] aDepartment of Medicine, Owen Clinic bDivision of Infectious Diseases, Department of Medicine cSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, San Diego, California, USA.

Article

DOI: 10.1097/01.aids.0000432466.15885.14

PubMed ID: 23842130

SO-VID: 86c19744-cba4-456b-a434-6826bcb78584

History

Data availability:

Comments

Comment on this article

scite_

Cited by 2

See all cited by